Kertruda 在三阴乳腺癌里被批准了

https://www.cancer.gov/news-events/cancer-currents-blog/2022/pembrolizumab-triple-negative-breast-cancer-improves-survival

“Among patients with a combined PD-L1 score of 10 or more, at 18 months after starting treatment, about 58% of patients in the combination-treatment group were still alive, compared with about 45% of those in the chemotherapy-alone group.”

Kertruda 是一种针对PD-1蛋白的抗体疗法，需要先测这个蛋白的配体PD-L1的表达量. 原理我以前写过 https://huaren.us/showtopic.html?topicid=2980052